Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control
NCT: NCT06667037 · ACTIVE_NOT_RECRUITING
Brief Summary
The purpose of this multicenter randomized clinical trial is to evaluate the myopia control effect of orthokeratology and 0.01% atropine sequential treatment in children and adolescents, as compared to continuous treatment with orthokeratology.
Frequently Asked Questions
What is Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control?
Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control is a clinical trial registered under NCT06667037. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT06667037?
The current status of NCT06667037 (Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control) is: ACTIVE_NOT_RECRUITING.
When did Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control start?
Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control started on 2024-09-21.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.